>
>
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter
LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) today announced that it has
LAVAL, QC and CAMBRIDGE, England, June 6, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced the voting results from
LAVAL, QC and CAMBRIDGE, England, May 23, 2022 /PRNewswire/ – Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), today announced that the first subject
Planned Phase 1a Single Ascending Dose (“SAD”) clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic (“PK”)
LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /PRNewswire/ – Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), today announced that it plans
LAVAL, QC, and CAMBRIDGE, England, May 9, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced
Planned Phase 1a Single Ascending Dose (“SAD”) clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full
Analysis of PK data from Phase 1 Multi-Ascending Dose (“MAD”) clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a
LAVAL, QC, and CAMBRIDGE, ENGLAND, March 7, 2022 /PRNewswire/ – Liminal BioSciences Inc. (NASDAQ: LMNL) (“Liminal BioSciences” or the “Company”), announced today that on March
